{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT02286518: Phase 1 Interventional Completed Clinical Pharmacology
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Meisoindigo ((E)-1,1'-dimethyl-[3,3'-biindolinylidene]-2,2'-dione) is a derivative of Indigo Naturalis, that has been used in China for chronic myeloid leukemia. In vitro cell line studies have shown that this agent might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). Meisoindigo has been a routine therapeutic agent in the clinical treatment of chronic myelogenous leukemia (CML) in China since the 1980s. In phase III clinical trial of Meisoindigo involving 402 patients, it was shown that Meisoindigo was equally efficient for both newly diagnosed and previously treated CML patients after oral administration. The hematological complete response (CR) and partial response (PR) rates, respectively, were 45.0 and 39.3% for newly diagnosed patients and 35.9 and 41.4% for previously treated patients. Meisoindigo was generally well tolerated. The most frequent
side‑effects were bone, joint and/or muscle pain of varying degrees when the dosage was more than the suitable one.
Status:
Investigational
Source:
NCT01924858: Phase 1 Interventional Terminated Alzheimer's Disease
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03692312: Phase 2/Phase 3 Interventional Completed Congenital Myotonic Dystrophy
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tideglusib (NP031112, NP-12, Nypta, Noscira SA, Madrid, Spain), a drug, which belongs to the thiadiazolidinone family, is a GSK-3β inhibitor. Tideglusib was in phase II clinical trials for the treatment of Alzheimer disease (AD) and progressive supranuclear palsy. Participants showed no benefit on either of the primary outcome measures or exploratory endpoints and further development in the drug was halted for these two disease. However, Tideglusib is on phase II clinical trial to determine whether drug is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
Class (Stereo):
CHEMICAL (RACEMIC)
Proflazepam is benzodiazepine derivative patented by Hoffmann-La Roche, F., und Co., A.-G. as anticonvulsant and muscle relaxant. In preclinical studies, Proflazepam shows activity in pentetrazole test and in the rotating rod test.
Class (Stereo):
CHEMICAL (RACEMIC)
Brolaconazole is imidazole derivative with potent antimicrobial activity against pathogenic fungi, molds, yeasts, and Gram-positive bacteria. Brolaconazole showed an inhibition band of 20-40 mM against Candida albican and it demonstrates higher activity compare bifonazole. Brolaconazole is useful for the treatment of dermal and vaginal infections such as vaginal candidiasis, tinea corporis, tinea pedis, tinea cruris, and other dermal infections.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Bremazocine, a kappa-opioid agonist has limited potential as a clinical analgesic, however, possesses a possible utility for the therapy of alcohol and drug addiction. It was shown that bremazocine-like drugs could lower intraocular pressure and to minimize ischemic damage, that could be used in the therapy of glaucoma and cardiovascular disease.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulisatin (also known as DAN-603) is an indolinone derivative patented by Andreu, Dr., S. A. as a laxative. In preclinical models, Sulisatin increases selectively the colon motility without modifying the speed of gastric, intestinal (small intestine) and caecal emptying in rats. Sulisatin is unable to inhibit water absorption in rat colon while small amounts of Sulisatin may inhibit it significantly.
Status:
Investigational
Source:
NCT00962585: Phase 2 Interventional Completed Menopause
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
EQUOL, (-)- is the (S)-enantiomer of the naturally-occurring isoflavandiol estrogen, equol. EQUOL, (-)- (US-131), is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor α (ERα). S-equol is the exclusive product of human intestinal bacterial synthesis from soy isoflavones. Two-Phase 1 studies have seen completed and published; AUS-131 was safe and well-tolerated in humans. A Phase 2a trial in menopausal women with vasomotor symptoms (VMS) has recently been completed (169 patients). A second Phase 2a trial in men with benign prostatic hyperplasia (BPH) is on track.
Status:
Investigational
Source:
NCT00120328: Phase 3 Interventional Terminated Diabetic Nephropathy
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Avosentan is an oral endothelin receptor A antagonist which was developed by Roche and then licensed by Speedel (now Novartis). The drug was tested in phase III of clinical trials in patients suffering from diabetic nephropathy, however drug development was terminated due to safety reasons: avosentan caused severe heart failure and even deaths.
Status:
Investigational
Source:
NCT00170911: Phase 2 Interventional Completed Osteoporosis
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Balicatib is a potent cathepsine K inhibitor that was developed for the treatment of knee osteoarthritis. The development of Balicatib was terminated in phase II due to the occurrence of skin rashes and rarer incidences of morphea-like skin changes.
